High expression of SLC7A1 in high‐grade serous ovarian cancer promotes tumor progression and is involved in MAPK / ERK pathway and EMT
Cancer Medicine · 2024
DOI: 10.1002/cam4.7217 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Shijing You und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China. Hauptthemen laut MEDLINE: Carcinoma, Ovarian Epithelial, Cystadenocarcinoma, Serous, Epithelial-Mesenchymal Transition, Gene Expression Regulation, Neoplastic. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Natural Science Foundation of Qingdao City, Natural Science Foundation of Qingdao Municipality.
Abstract (Originalsprache)
Our previous studies have shown that upregulation of SLC7A1 in epithelial ovarian cancer (EOC) tumor cells significantly increases cancer cell proliferation, migration, and cisplatin resistance; however, the molecular mechanism by which SLC7A1 functions in EOC remains unknown. In later studies, we found that SLC7A1 is also highly expressed in the interstitial portion of high‐grade serous ovarian cancer (HGSOC), but the significance of this high expression in the interstitial remains unclear. Here, we showed the Interstitial high expression of SLC7A1 in HGSOC by immunohistochemistry. SLC7A1 enriched in cancer‐associated fibroblasts (CAFs) was upregulated by TGF‐β1. Transwell assay, scratch assay, cck8 assay and cell adhesion assay showed that SLC7A1 highly expressed in CAFs promoted tumor cells invasion, migration and metastasis in vitro. The effect of SLC7A1 on MAPK and EMT pathway proteins in ovarian cancer (OC) was verified by RNA sequencing and western blotting. Overexpression of SLC7A1 in OC is involved in MAPK/ ERK pathway and EMT. In general, in HGSOC, CAFs overexpressing SLC7A1 supported the migration and invasion of tumor cells; SLC7A1 is highly expressed in ovarian cancer and is involved in ERK phosphorylation and EMT signaling in MAPK signaling pathway. This suggests that SLC7A1 may be a potential therapeutic target for OC metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
- Department of Gynecological Oncology, Affiliated Qingdao Central Hospital of Qingdao University, Qingdao, Shandong, China.
ORCID-Profile: Shijing You
Förderung
- The Natural Science Foundation of Qingdao City
- Natural Science Foundation of Qingdao Municipality
Zitieren
APA
You, S., Han, X., Xu, Y., Sui, L., Song, K., & Yao, Q. (2024). High expression of SLC7A1 in high‐grade serous ovarian cancer promotes tumor progression and is involved in MAPK / ERK pathway and EMT. Cancer Medicine. https://doi.org/10.1002/cam4.7217
Vancouver
You S, Han X, Xu Y, Sui L, Song K, Yao Q. High expression of SLC7A1 in high‐grade serous ovarian cancer promotes tumor progression and is involved in MAPK / ERK pathway and EMT. Cancer Medicine. 2024. doi:10.1002/cam4.7217
BibTeX
@article{You2024,
author = {You, Shijing and Han, Xiahui and Xu, Yuance and Sui, Lei and Song, Kejuan and Yao, Qin},
title = {High expression of SLC7A1 in high‐grade serous ovarian cancer promotes tumor progression and is involved in MAPK / ERK pathway and EMT},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.7217}
}
EUVIMED